Reconnecting

The current page stays visible while onset.to reconnects in the background.

Microdosing for Depression Appears to Work About as Well as Drinking Coffee

Open original

Microdosing LSD for clinical depression appears to offer little or no advantage over placebo in a Phase 2B trial, with reported mood and well-being changes not translating into statistically meaningful improvement on standard depression scales. The trial by Melbourne-based MindBio Therapeutics tested small LSD doses (about 4 to 20 micrograms) over eight weeks in 89 adults with major depressive disorder. Outcomes measured with the Montgomery-Åsberg Depression Rating Scale (MADRS) favored an active placebo strategy rather than LSD, with caffeine used as a comparison. The article places these results in the broader context of microdosing claims and placebo effects in psychedelic research, including how expectation and trial design (for example, double-dummy blinding with active placebos) can shape participants' perceived effects. It also contrasts this Phase 2B outcome with MindBio's earlier open-label findings and notes concerns about legal risk around LSD.